

Food and Drug Administration Rockville, MD 20857

NDA 20-181/S-001

Abbott Laboratories Hospital Products Division D-389, Building AP30 200 Abbott Park Road Abbott Park, Illinois 60064-6157

Attention: Jean Kirkeleit Davis

Manager, Regulatory Affairs

Dear Ms. Davis:

Please refer to your supplemental new drug application dated September 12, 2002, received September 13, 2002, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Liposyn® III 30% (I.V. Fat Emulsion) Pharmacy Bulk Package.

We acknowledge receipt of your submissions dated December 5, 2002 and February 18, 2003.

The "Changes Being Effected" supplemental new drug application provides for a revised package insert and immediate container label per the requirements of 21 CFR 201.323 and revised release and stability specifications, which include a test for aluminum determination with the acceptance criterion of "NMT 25 mcg/L of aluminum."

We have completed our review of this application, as amended, and it is approved, effective on the date of this letter.

If you issue a letter communicating important information about this drug product (i.e., a "Dear Health Care Professional" letter), we request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH, HF-2 FDA 5600 Fishers Lane Rockville, MD 20857

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Victoria Kao, Regulatory Project Manager, at (301) 827-7416.

Sincerely,

{See appended electronic signature page}

Bob Rappaport, M.D.
Acting Director
Division of Anesthetic, Critical Care,
And Addiction Drug Products
Office of Drug Evaluation II
Center for Drug Evaluation and Research

This is a representation of an electronic record that was signed electronically a	nd
this page is the manifestation of the electronic signature.	

/s/

Bob Rappaport 3/12/03 05:44:47 PM